Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion type Assertion NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_head.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion description "[Therapy with HER-2-retargeted oncolytic HSV could be effective in combined or sequential protocols with monoclonal antibodies and small inhibitors, particularly in patients resistant to HER-2-targeted therapy because of alterations in HER-2 signaling pathway, or against brain metastases inaccessible to anti-HER-2 antibodies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_provenance.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion evidence source_evidence_literature NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_provenance.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion SIO_000772 19458262 NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_provenance.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion wasDerivedFrom befree-2016 NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_provenance.
- NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_assertion wasGeneratedBy ECO_0000203 NP740268.RAcaanXZNPNO9FKtv97-jToVsbpKZJzZoFXRt4b3ZYhw4130_provenance.